Search

Displaying results 1051 - 1060 of 7674 in total
  1. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    [A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile

  2. Drug

    Lenacapavir

    go.drugbank.com/drugs/DB15673
    ApprovedInvestigational

    HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]

  3. Drug

    Alprazolam

    go.drugbank.com/drugs/DB00404
    ApprovedIllicitInvestigational

    [A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148] … [A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.

    Mixtures: NEUPAX DUO-SProducts: Nu-alpraz Tab 0.5mg, Nu-alpraz Tab 0.25mg
  4. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.

  5. Drug

    Enflurane

    go.drugbank.com/drugs/DB00228
    ApprovedVet approvedWithdrawn

    Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.

  6. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.

  7. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    [L35505] Stratagraft was in the early stages of development as far back as 2009[A237275] and was granted full FDA approval in June 2021.[L35525] … The product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting.

  8. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    [A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. … It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]

  9. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … [L39060] In June 2023, the FDA approved the use of somatrogon also for the treatment of pediatric growth hormone deficiency.

  10. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver